Scarica l'app Stockscreener
11.40
7.55%
0.80
Pre-mercato:
11.50
0.10
+0.88%
Precedente Chiudi:
$10.60
Aprire:
$10.55
Volume 24 ore:
750.44K
Relative Volume:
0.76
Capitalizzazione di mercato:
$458.06M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+6.24%
1M Prestazione:
+14.80%
6M Prestazione:
-46.60%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$10.48
$11.41
Intervallo di 1 settimana:
$10.26
$11.41
Portata 52W:
$4.17
$28.99
Septerna Inc Stock (SEPN) Company Profile
Nome
Septerna Inc
Settore
Industria
Telefono
650-338-3533
Indirizzo
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Confronta SEPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
11.40 | 458.06M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-19 | Iniziato | JP Morgan | Overweight |
| 2024-11-19 | Iniziato | TD Cowen | Buy |
| 2024-11-19 | Iniziato | Wells Fargo | Overweight |
Septerna Inc Borsa (SEPN) Ultime notizie
Septerna, Inc. Holds Virtual Annual Stockholders Meeting - TipRanks
Driehaus Capital Management LLC Increases Stake in Septerna Inc - GuruFocus
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies - MSN
Nuveen Asset Management LLC Buys New Stake in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Bank of America Corp DE Makes New Investment in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Kalkine: Septerna Inc Gains Traction on NASDAQ 100 Index from Kalkine - Kalkine Media
Septerna To Present At Jefferies Conference; SEP-631 Phase 1 Trial On Track For Q3 - Nasdaq
Deutsche Bank AG Invests $239,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Septerna to Present at Jefferies Global Healthcare Conference - The Manila Times
GPCR Pioneer Septerna Reveals Latest Drug Discovery Progress at Major Jefferies Healthcare Event - Stock Titan
Jane Street Group LLC Invests $600,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Analysts Think These Stocks Could More Than Double in Value - Investing.com
Analysts Think These Stocks Could More Than Double in Value - MarketBeat
Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect? - MSN
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled - MSN
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Globe and Mail
Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal - MSN
Cantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN) - The Globe and Mail
Wells Fargo & Company Boosts Septerna (NASDAQ:SEPN) Price Target to $18.00 - Defense World
Septerna First Quarter 2025 Earnings: US$0.49 loss per share (vs US$6.35 loss in 1Q 2024) - simplywall.st
22,095 Shares in Septerna, Inc. (NASDAQ:SEPN) Bought by The Manufacturers Life Insurance Company - Defense World
ETFs to Capitalize on the Novo Nordisk-Septerna Deal - MSN
Novo Nordisk in pact with Septerna for oral obesity drugs - MSN
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - MSN
Septerna: Novo's Investment In Incretin Program IntriguesOne For The Watchlist - Seeking Alpha
Where Septerna Stands With Analysts - Benzinga
Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash - Seeking Alpha
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight - Investing.com
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership - PMLiVE
Septerna price target raised to $18 from $11 at Wells Fargo - TipRanks
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - MSN
Biotech Stocks Worth Watching – May 14th - Defense World
Novo Nordisk (NVO) Deal Highlights Strategic Potential Amid Septerna Developments | NVO Stock News - GuruFocus
Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating - TipRanks
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna - MSN
Septerna reports Q1 EPS (49c), consensus (45c) - TipRanks
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - The Manila Times
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk - MSN
Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments - MSN
Novo Nordisk, Septerna collaborate on developing GPCR therapies - World Pharmaceutical Frontiers
Novo Nordisk Partners with Septerna for New Obesity Drug Development - GuruFocus
Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal - Law360
Novo Nordisk Looks To Septerna For Oral Obesity Options - insights.citeline.com
Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
Septerna Inc Azioni (SEPN) Dati Finanziari
Non sono disponibili dati finanziari per Septerna Inc (SEPN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Septerna Inc Azioni (SEPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Finer Jeffrey | CEO and President |
Apr 03 '25 |
Option Exercise |
2.76 |
5,000 |
13,800 |
826,907 |
| Ezekowitz Alan | Director |
Mar 07 '25 |
Buy |
6.93 |
13,319 |
92,270 |
117,420 |
| Ezekowitz Alan | Director |
Mar 06 '25 |
Buy |
6.00 |
41,355 |
248,130 |
104,101 |
| Ezekowitz Alan | Director |
Mar 05 '25 |
Buy |
5.82 |
37,835 |
220,260 |
62,746 |
| Ezekowitz Alan | Director |
Mar 04 '25 |
Buy |
6.35 |
7,491 |
47,544 |
24,911 |
| Finer Jeffrey | CEO and President |
Feb 25 '25 |
Buy |
5.68 |
10,000 |
56,765 |
764,907 |
| Finer Jeffrey | CEO and President |
Feb 26 '25 |
Buy |
5.70 |
4,000 |
22,796 |
768,907 |
| Finer Jeffrey | CEO and President |
Feb 27 '25 |
Buy |
5.80 |
3,000 |
17,400 |
771,907 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 25 '25 |
Buy |
5.59 |
6,282 |
35,116 |
36,282 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 27 '25 |
Buy |
5.85 |
3,718 |
21,750 |
40,000 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):